Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Meda

- PMLiVE

Building a bright future

Mylan takes a bold approach as it doubles its pipeline through R&D and acquisitions

- PMLiVE

Teva faces early rival to longer-acting Copaxone in US

US regulator approves Mylan’s MS drug

- PMLiVE

FDA panel backs Avastin and Herceptin biosimilars

A decision from the US regulator is expected in September

- PMLiVE

Mylan deal with Roche clears path to biosimilar Herceptin launch

Covers global markets with the exception of Japan, Brazil and Mexico

- PMLiVE

Stada opens books to let formal bidding commence

Cinven, Advent International and Bain Capital now have opportunity to revise their bids

- PMLiVE

Advent tops Cinven offer for Stada as third suitor looms

Values the OTC and generics specialist at €3.6bn, with offer open until 27 February

- PMLiVE

Stada confirms Cinven as one of two takeover bidders

Private equity group offers €3.6bn for the generics and over-the-counter medicines manufacturer

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

Takeda agrees $5.2bn deal to buy Ariad

Acquires cancer firm in the first big pharma M&A deal of 2017

- PMLiVE

Mylan facing US anticompetitive practice probe

Senate judiciary committee calls for fair competition review over EpiPen sales

- PMLiVE

Torrid times at Gilead lead to calls for a major M&A deal

HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa

Pricing’s dodos

Mylan isn’t alone in its outdated practices

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links